Compare Summit Therapeutics Inc (SMMT) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Teradyne, Inc. — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Teradyne, Inc. trades at $402.68 (market cap $62.34B). The key difference: Teradyne, Inc. is far larger — about 4.5× Summit Therapeutics Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Teradyne, Inc. for 37 Days on average.
| SMMT | TER | |
|---|---|---|
Market Cap | $13.71B | $62.34B |
Volume | 6,173,057 | 3,368,404 |
Sector | Health | Technology |
52-Week High | $26.38 | $483.84 |
52-Week Low | $12.43 | $132.05 |
Typical Hold Time | 16 Days | 37 Days |
Enterprise Value | $13.04B | $62.08B |
Dividend Yield | — | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Teradyne (TER) trades at $398.72, down 3.17% on the day, but maintains a bullish technical outlook with strong support at $388 and resistance at $410. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.47 exceeding the $2.09 estimate. Revenue for 2025 reached $3.19 billion, and net income margin stands at 25.77%. Recent developments include the launch of the Magnum E2 memory test system and Iris 100 for microLED devices, targeting AI and high-performance computing demand.
The outlook for TER is positive, driven by AI-driven test equipment demand and consistent earnings outperformance. Risks include reliance on semiconductor cycles and competitive pressure from peers like KLAC. Analysts are bullish with a consensus price target of $461.50, representing a 15.7% upside from the current price. Institutional buying and a lack of sell ratings underscore confidence in growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
